Celyad Oncology S.A.
0QFK.L
Price:
$0.8
Market Cap:
$13.41M
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's precl...[Read more]
Industry
Medical - Pharmaceuticals
IPO Date
2014-01-08
Stock Exchange
LSE
Ticker
0QFK.L
PE Ratio
[-0.55]
ROE
[90.60%]
Current Ratio
[2.29]
Dividend Yield
[0%]
Enterprise Value
[26.75M]
Dividend History
The ROE as of July 2025 (TTM) for Celyad Oncology S.A. (0QFK.L) is 90.60%
According to Celyad Oncology S.A.’s latest financial reports and current stock price. The company's current ROE is 90.60%. This represents a change of -170.00% compared to the average of -129.43% of the last 4 quarters.
Celyad Oncology S.A. (0QFK.L) Historical ROE (quarterly & annually)
How has 0QFK.L ROE performed in the past?
The mean historical ROE of Celyad Oncology S.A. over the last ten years is -146.21%. The current 90.60% ROE has changed -161.96% with respect to the historical average. Over the past ten years (40 quarters), 0QFK.L's ROE was at its highest in in the June 2013 quarter at 572.91%. The ROE was at its lowest in in the June 2023 quarter at -367.03%.
Average
-146.21%
Median
-61.76%
Minimum
-948.23%
Maximum
36.13%
Celyad Oncology S.A. (0QFK.L) ROE by Quarter and Year
Discovering the peaks and valleys of Celyad Oncology S.A. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.46%
Maximum Annual ROE = 36.13%
Minimum Annual Increase = -126.96%
Minimum Annual ROE = -948.23%
| Year | ROE | Change |
|---|---|---|
| 2024 | 36.13% | -126.96% |
| 2023 | -134.01% | -85.87% |
| 2022 | -948.23% | 1.46% |
| 2021 | -60.75% | 7.59% |
| 2020 | -56.47% | -10.03% |
| 2019 | -62.76% | -3.92% |
| 2018 | -65.32% | -44.94% |
| 2017 | -118.64% | 356.76% |
| 2016 | -25.97% | -0.55% |
| 2015 | -26.12% | -57.64% |
Celyad Oncology S.A. (0QFK.L) Average ROE
How has 0QFK.L ROE performed in the past?
The current ROE of Celyad Oncology S.A. (0QFK.L) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-348.70%
5-year avg
-232.67%
10-year avg
-146.21%
Celyad Oncology S.A. (0QFK.L) ROE vs. Peers
How is 0QFK.L’s ROE compared to its peers?
Celyad Oncology S.A.’s ROE is
| Company | ROE | Market cap |
|---|
Build a custom stock screener for Celyad Oncology S.A. (0QFK.L) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Celyad Oncology S.A. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Celyad Oncology S.A. (0QFK.L) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Celyad Oncology S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Celyad Oncology S.A.'s ROE?
How is the ROE calculated for Celyad Oncology S.A. (0QFK.L)?
What is the highest ROE for Celyad Oncology S.A. (0QFK.L)?
What is the 3-year average ROE for Celyad Oncology S.A. (0QFK.L)?
What is the 5-year average ROE for Celyad Oncology S.A. (0QFK.L)?
How does the current ROE for Celyad Oncology S.A. (0QFK.L) compare to its historical average?